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Background: Tongue squamous cell carcinoma is the most common squamous cell carcinoma of the head and 
neck. Immunotherapy has great potential in the treatment of tongue squamous cell carcinoma because of its 
unique advantages. However, the efficacy of immunotherapy is limited by the efficiency of antigen phagocytosis 
by immune cells. 
Material and Methods: We extracted dendritic cells (DCs) from human peripheral blood. Utilizing a nanosec-
ond pulsed electric field (nsPEF), we deliver the tumour lysate protein into DCs and then incubate the DCs with 
PBMCs to obtain specific T cells to kill tumour cells. The biosafety of nsPEF was evaluated by the ANNEXIN 
V-FITC/PI kit. The efficacy of lysate protein delivery was evaluated by flow cytometry. The antitumour efficacy 
was tested by CCK-8 assay.
Results: The nsPEF of the appropriate field strength can significantly improve the phagocytic ability of DCs to 
tumour lysing proteins and have good biosafety. The tumour cell killing rate of the nsPEF group was higher than 
the other group (p < 0.05).
Conclusions: Utilizing nsPEF to improve the phagocytic and presenting ability of DCs could greatly activate the 
adaptive immune cells to enhance the immunotherapeutic effect on tongue squamous cell carcinoma. 




Cancer is one of the deadliest human diseases and has 
proved difficult to treat. According to WHO statistics, 
the worldwide morbidity and mortality rates of cancer 
are high (1). Traditional treatments, such as surgery, 
radiotherapy and chemotherapy, have only increased 
the median progression-free survival to some extent; 
however, they are still unable to overcome drug resis-
tance, metastasis and serious side effects and defects 
(2-5). In recent years, tumour immunotherapy has at-
tracted increasing interest due to its high efficiency, 
high specificity and cascade amplification. The key to 
tumour immunotherapy is the modification of primary 
presenting cells (6-11). Antigen presenting cells (APCs), 
which are a subtype of immune cells, include dendritic 
cells (DCs), macrophages, and B cells. APCs capture 
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exogenous or endogenous proteins and in turn activate 
the adaptive immune cells to generate an inflammatory 
response or tolerance immune response (12). In tumour 
immunotherapy, APCs digest tumour proteins and pres-
ent them to immature T cells to activate their tumour 
killing function (13,14). Immunotherapy based on DCs 
has shown excellent treatment efficacy for many can-
cers, such as gliomas, cervical cancer, prostate cancer, 
and malignant melanoma (15-17). However, the weak 
immunogenicity of tumour antigens and the low effi-
ciency of antigen phagocytosis potently limit the effect 
of immunotherapy. Many research groups have attempt-
ed to overcome these problems (12). For example, nano-
tubes have been used to carry tumour lysate proteins 
to enhance the phagocytosis of tumour lysate proteins 
by DCs, thereby increasing the anti-tumour effect (18). 
HADJATI et al. strengthened immunotherapy by using 
mouse toxoplasmosis to enhance the antigen phagocy-
tosis and presentation function of DCs. LANGER et al. 
(19) used microfluidic technology to induce transient 
cell membrane perforation and increase antigen uptake, 
thereby improving the efficacy of tumour immunother-
apy. JAMAL et al. (20) fabricated a vehicle based on 
carbon nanotubes for delivering tumour antigens and 
adjuvants to enhance the effectiveness of tumour im-
munotherapy (21). 
Nanosecond pulsed electric field (nsPEF) can generate 
instantaneous cell membrane perforation to efficiently 
mediate macromolecule entry into cells (22,23). For ex-
ample, nsPEF can be used to mediate plasmid entry into 
cells and support efficient expression. The synergistic 
effects of nsPEF combined with gemcitabine have been 
shown to promote the treatment of malignant melanoma 
and oral squamous cell carcinoma (21-24). In addition, 
this modality has many advantages, such as minimal 
side effects, high biocompatibility and tumour-specific 
cytotoxicity (25). Because of these unique advantages, 
we established a method based on nsPEF technology 
to improve the treatment of tongue squamous cell car-
cinoma. Furthermore, we confirmed the improvement 
in the antigen presenting ability of DC phagocytes by 
nanosecond pulsed stimulation.
Materials and Methods
- Mononuclear cells (PBMC) were extracted from the 
peripheral blood of participants
Venous blood (30 mL) was extracted from healthy vol-
unteers using a disposable anticoagulation tube (BD, 
Lake Franklin, New Jersey, USA) under the approval of 
the Institutional Review Board (IRB) at the Hospital of 
Stomatology of Lanzhou University, Lanzhou, Gansu, 
China. Volunteers consented to the use of their blood 
samples for this study before collection. Under sterile 
conditions, the anticoagulation tube was removed and 
placed in a 50 mL centrifuge tube (Corning, Corning, 
New York, USA). The peripheral blood mononuclear 
cells (PBMCs) were extracted by Human Lymphocyte 
Separation Medium (TBD, Tianjin, China). The cells 
were suspended in RPMI 1640 (Gibco, Grand Island, 
New York, USA) + 10% FBS (Gibco, Grand Island, 
New York, USA) complete medium, and the final con-
centration of the PBMCs was 2 × 105/mL.
- Isolation and induction of mature DCs
Freshly isolated PBMCs were resuspended in RPMI 
complete medium, and the cell density was adjusted to 
4 × 106/mL (5 mL). Then, the cells were cultured in a 
T25 flask (Corning, Corning, New York, USA) (37 °C, 
4 h, 5% CO2) in an incubator, and the culture super-
natant and non-adherent cells were discarded by sterile 
straw aspiration. The bottle was carefully washed with 
preheated RPMI 1640 + 10% FBS complete medium to 
obtain relatively pure adherent mononuclear cells, and 
5 mL of RPMI 1640 + 10% FBS complete medium was 
added to the culture flask. Then, 5 μL of rhGM-CSF 
(R&D Systems, Minneapolis, Minnesota, USA) and 4 
μL of rhIL-4 (Beyotime Biotechnology, Shanghai, Chi-
na) were added. After culturing in the incubator for 6 
d (37 °C, 5% CO2), the immature DCs were obtained.
TNF-α (Beyotime Biotechnology, Shanghai, China) (20 
ng/mL) was added to the immature DCs, and after 2 
d of culture, the DCs became larger and clustered into 
mature DCs.
- Preparation of Cal-27 lysate protein 
Cal-27 tongue squamous cell carcinoma cells (ATCC) 
were maintained in Dulbecco’s modified Eagle medi-
um (DMEM) (Gibco, Grand Island, New York, USA) 
supplemented with 10% FBS, L-glutamine (Beyotime 
Biotechnology, Shanghai, China) and penicillin/strep-
tomycin (Beyotime Biotechnology, Shanghai, China) at 
37 °C, 5% CO2 and saturated humidity. The cells were 
cultured to the logarithmic phase and passaged and 
cryopreserved by routine methods.
To digest the Cal-27 cells in the logarithmic growth 
phase, the cells were treated with 0.25% trypsin (Hy-
Clone, Logan, Utah, USA). Then, the culture medium 
was removed, the sample was washed with D-Hank’s 
buffer solution 2 times and centrifuged (1000 r/min, 
5 min), and the cell sedimentation was then collected. 
Cell lysis solution (Beyotime Biotechnology, Shanghai, 
China) was then added to each well at a volume of 1 mL 
to obtain the lysate. The cell mixture was placed at 4 
°C for 0.5 h and then centrifuged for 5 min at 12,000 g. 
The supernatant was Cal-27 cell lysate protein, and 50 
μL was removed and placed in the tube to determine the 
protein concentration. The remainder was stored at -80 
°C. The protein concentration was determined using the 
BCA kit (Beyotime Biotechnology, Shanghai, China).
- Tumour antigen-sensitized DCs
Immature DCs were harvested for 6 d, and the cells 
were counted. The cell concentration was adjusted to 
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2 × 105/mL with 10% FBS containing RPMI 1640 me-
dium and added to 24-well plates (Corning, Corning, 
New York, USA) at a volume of l mL per well. A total of 
4 wells were used as follows: DC well, TumourP-treated 
well, nsPEF-treated well, TumourP and nsPEF-treated 
well. The DC well had no stimulant, and the other three 
wells were treated with TumourP, nsPEF stimulation, 
TumourP and nsPEF stimulation. The protein concen-
tration in each group was 0.1 μg/mL to sensitize the 
DCs. In addition, 20 ng/mL TNF-α was added to obtain 
mature DCs at 37 °C under the 5% CO2 culture condi-
tions for 2 d.
- Homologous mixed lymphocyte reactions
Peripheral blood samples were collected from the same 
source as the DCs of the healthy volunteers. PBMCs 
were separated using the Ficoll density gradient meth-
od, and the cell density was adjusted to 2 × 106/mL. 
Different antigens and mature DCs (DC: PBMC=1:10) 
were added and incubated for 3-5 d (D 37 °C, 5% CO2) 
to obtain mixed lymphocytes.
- Detection of the killing effect of mixed lymphocytes 
on Cal-27 cells
Cal-27 cells were incubated in 96-well plates (Corn-
ing, Corning, New York, USA), with 5000 cells per 
well. After incubation for 4 h (37 °C, 5% CO2), adherent 
cells were regarded as target cells (T). After co-culture 
with the DCs, the PBMCs were extracted as effector 
cells (E). The cell density was adjusted to 2 × 106/mL 
with RPMI 1640 complete medium, and we then added 
PBMCs to each well in different proportions (E: T= 40: 
1, 20: 1, 10: 1, 5: 1). Each group consisted of 6 parallel 
wells. After incubation for 2-3 d (37 °C, 5% CO2), the 
suspended lymphocytes were removed from each well. 
Almost no lymphocytes were observed in each well un-
der a microscope.
- Tumour killing rate detected by CCK-8:
A total of 100 μL of RPMI complete medium was added 
to a 96-well plate with a blank well containing only me-
dium and CCK-8 reagent and no targets as the back-
ground value (DOJINDO, Kyushu, Japan). Then, 10 μL 
of CCK-8 solution was added to each well and reacted 
without light for 4 h at 37 °C. The A450 absorbance 
value was then measured. The kill rate was calculated 
using the following formula: (Fig.1)
A450 (treated group) - A450 (background)
kill efficiency = [1 -——————————— × 100% 
A450 (control group) - A450 (background)
- Flow cytometry to detect DC phagocytosis of the tu-
mour lysate protein
Following the instructions of the ReadLink antibody la-
belling kits (AAT Bioquest, Sunnyvale, CA, USA), Cal-
27 lysate protein (1 mg/mL) was mixed with FITC dye 
molecules and dissolved in reaction buffer. Exposure to 
light was avoided for 30-60 min. FITC-labelled tumour 
protein (TumourP-FITC) was obtained by adding an ap-
propriate quencher for 10 min to remove unbound FITC.
We harvested immature DCs after 6 d. The cells were 
placed in a 24-well plate at a density of 3-5 × 105 cells/
per well. The wells were grouped as follows: 1) control 
DCs, which was without antigen; 2) adsorptive fluores-
cence control group, in which TumourP-FITC with a 
protein concentration of 1 μg/mL was added to the DCs 
in an ice bath for 4 h; 3) phagocytic group, in which 
DCs were added to a protein concentration of 1 μg/mL 
FITC and incubated at 37 °C under 5% CO2 for 4 h; and 
4) a nanosecond pulsed group, in which TumourP-FITC 
with a protein concentration of 1 μg/mL was added and 
incubated for 4 h at 37 °C under 5% CO2 for protein 
phagocytosis. After 4 h, the cells were collected and 
centrifuged at 1500 r/min for 10 min. The supernatant 
was removed and the cells were collected and washed 
with D-Hank’s buffer twice to remove the non-phago-
cytic protein. The positive rate and mean fluorescence 
intensity of DC phagocytosis with FITC-TumourP were 
then detected by flow cytometry.
- nsPEF acts on the safety of immature DCs
DC apoptosis was detected using the ANNEXIN V-
FITC/PI kit (Solarbio Life Sciences, Beijing, China). 
The mature DCs were resuspended in pre-cooled 1 × 
PBS (HyClone, Logan, Utah, USA) (4 °C) and centri-
fuged at 2000 rpm for 5 to 10 min to wash the cells. A 
total of 300 μL of 1 × Binding Buffer suspension cells 
was added. After adding 5 μL of Annexin V-FITC, the 
cells were incubated for 5 min, and 5 μL of PI staining 
was then added for 5 min before detection. DC apopto-
sis was detected by flow cytometry.
- Statistical analysis
More than three independent experiments are conduct-
ed for each experiment. All data were analysed by SPSS 
16.0 through t test method. P < 0.05 was considered sta-
tistically significant.
Results 
- Extraction of dendritic cells and acquisition of tumour 
lysate proteins
We collected blood samples from the volunteers and 
extracted PBMCs using a human peripheral blood 
lymphocyte separation solution. As shown in Fig. 2A, 
mononuclear cells were obtained by adherent separa-
tion and observed via optical microscopy. Dendritic 
cells were obtained by the induction of rhGM-CSF and 
rhIL-4 cytokines. We observed the cell characteristics 
via microscopy. As shown in Fig. 2B, the results indi-
cated that the number and volume of cells increased. 
The dendritic protrusion appeared on the cell surface, 
and cell aggregation was observed. The results of the 
above cell morphological studies indicated that DCs 
were successfully extracted and induced. The experi-
ment was repeated three times.
Fig. 1: Formula.
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The BCA results are presented in Fig. 2C, and they show 
that an appropriate concentration of Cal-27 tumour lys-
ing protein was obtained to meet the needs of the follow-
up analyses. The experiment was repeated three times.
- nsPEF affects the survival of immature DCs
The cell apoptotic assay results are shown in Fig. 2D. 
These data suggest that in the range of 5-10 kV, the ratio 
of Annexin V to PI positive cells did not change signifi-
cantly between the experimental group and the control 
group. The results revealed that the pulse generated a 
reversible instantaneous hole on the cell membrane and 
did not cause cell apoptosis. In the 15-20 kV range, the 
ratio of Annexin V to PI positive cells increased slight-
ly, indicating that the nsPEF in this range caused a small 
amount of irreversible membrane perforation and cell 
apoptosis. The experiment was repeated three times.
- Flow detection of DC phagocytosis of tumour lysate 
proteins
The flow detection experimental results (Fig. 3) show 
that the phagocytic volume of tumour lysing protein is 
increased by one fold compared with that of the non-
nsPEF group with 5 kV and 20 kV nanosecond pulsed 
fields. These results suggest that a nsPEF of the ap-
propriate field strength can significantly improve the 
phagocytic ability of DCs to tumour lysing proteins. 
The experiment was repeated three times.
- Effect of mixed lymphocytes on tumour cells
As shown in Fig. 4A, Cal-27 cells were observed to ad-
here to specific T cells, died after a period of time, and 
were broken down into cell debris. The results of the cy-
totoxicity test are presented in Fig. 4B. The tumour cell 
killing rate of the experimental group was increased by 
Fig. 3. Flow detection of DC phagocytosis of tumour lysate proteins. (n≥3 independent experiments).
Fig. 2. Extraction of lysate proteins from Cal-27 cells and the biosafety of nsPEF. (A) Mononucle-
ar cells extracted from peripheral blood. (B) Dendritic cells were obtained by in vitro culture and 
cytokine stimulation. (C) The concentration of Cal-27 lysate protein was measured by the BCA 
Protein Assay Kit. The standard curve is shown in the figure. (D) nsPEF affects the survival of 
immature DCs (n≥3 independent experiments).
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the application of nsPEF. The experiment was repeated 
three times.
Discussion
Previous studies have shown that the weak immuno-
genicity of tumour antigens and the low efficiency of 
antigen phagocytosis potently limit the effect of immu-
notherapy. We utilized nsPEF, which assists macromol-
ecule entry into the cell, to increase the efficiency of 
antigen phagocytosis and improve immunotherapy. 
Loaded tumour proteins are the basis of tumour im-
munotherapy, and different antigen loading methods 
will affect the major histocompatibility complex type I 
and type II antigen presentation pathways, respectively, 
which triggers CD8+ and CD4+ T lymphocyte activa-
tion. At present, the loading method primarily includes 
protein polypeptide delivery, necrotic tumour cells, tu-
mour lysates, and genetic engineering. Protein polypep-
tide delivery and genetic engineering have specific ad-
vantages, but resolving the tumour heterogeneity of the 
immune escape is difficult because of the single pheno-
type. Therefore, considering the heterogeneity of the tu-
mour and the specificity of the immune cell phenotype 
and other factors, we chose to load tumour lysing pro-
teins, which include all the tumour antigen phenotypes 
(26). We used tumour lysates and protease inhibitors to 
extract tumour lysate proteins. This method can be used 
to obtain all the tumour epitopes of tumour cells and is 
suitable for clinical application.
The cell membrane is an important barrier to maintain 
cell viability and function. Its main structure consists of 
a phospholipid bilayer layer that has a degree of mobil-
ity. The cell membrane generates transient holes under 
appropriate external stimulation. However, if the exter-
nal stimulation is too strong, it will cause irreversible 
damage to the cell membrane structure, which will lead 
to cell apoptosis and necrosis. According to previous 
studies, the nsPEF can enhance the efficiency of extra-
cellular macromolecule cell entry under appropriate pa-
rameters by generating transient holes in the cell mem-
Fig. 4. Effect of mixed lymphocytes on tumour cells. (A) Mature DCs sensitized PBMCs to obtain mixed 
lymphocytes containing specific T cells, which were co-cultured with Cal-27 cells, and the results of light 
microscopy are shown in the figure. From left to right, the ratio of lymphocytes to Cal-27 cells decreases. 
The red arrow points to cancer cell death fragments. (B) Killing efficacy (p<0.05). All data are presented as 
means± standard deviations (n≥3 independent experiments).
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brane. To obtain the biological completeness range of 
the nsPEF intensity, we used an apoptotic kit to perform 
flow cytometry on the cells after treatment. The results 
demonstrated that our experimental protocol has good 
biosecurity. 
After confirming the biosecurity of nsPEF, we evalu-
ated the phagocytosis of tumour lysing protein, which 
is the key step in the antigen presentation of DCs. After 
phagocytosis, the DCs can treat the antigen and then 
present to the lymphocytes through the main histocom-
patibility antigen presentation pathway, thus causing 
subsequent antigen-specific immune responses. The 
phagocytosis process of the DCs is regulated by the 
identification of the antigen, which is affected by the 
different phenotypes or physical and chemical proper-
ties. The nsPEF causes instantaneous perforation of the 
membrane, and biological macromolecules, including 
various antigens, can enter the cytoplasm through free 
diffusion. To evaluate this effect, we used flow cytom-
etry for detection. We used a method reported in the 
literature to obtain fluorescent labelled Cal-27 lysate 
protein in advance, apply nanosecond pulses at preset 
parameters, and perform flow cytometry. The average 
fluorescence intensity of the cells is positively corre-
lated with cell phagocytosis. The results suggest that a 
nsPEF of the appropriate field strength can significantly 
improve the phagocytic ability of DCs for tumour lys-
ing proteins.
T lymphocyte-mediated target cell killing is the ultimate 
step in tumour immunotherapy and is the most funda-
mental indicator of antitumour efficacy. The results of 
the cytotoxicity test showed that the tumour cell killing 
rate of the experimental group was increased by the ap-
plication of nsPEF. This killing process is based on the 
phagocytosis and presentation of DC antigens; thus, the 
initial T cells in combination with DCs presented the 
antigen, which resulted in activation, followed by pro-
liferation and differentiation into cytotoxic T cells un-
der the action of cytokines. The final cytotoxic T-cell-
secreting adhesion molecules bind to the corresponding 
target cells through the perforin/granzyme pathway and 
Fas/FasL pathway to kill the target cells. 
The phenotypic differences between tumour cells and 
normal cells are obscure, and killing tumour cells with-
out side effects is difficult. In addition, the prolifera-
tion and progression of tumour cells are uncontrollable; 
therefore, completely eliminating the tumour with sur-
gical treatment, radiotherapy, chemotherapy and other 
traditional methods is difficult. The immune system has 
a specific antitumour ability. The immune response can 
be amplified through a cascade and has the character-
istics of immune memory; therefore, tumour immuno-
therapy has the potential to completely cure tumours. 
However, a number of challenges remain for immuno-
therapy due to the adaptation of tumour tissue to the 
patient’s own immune system, including the low im-
munogenicity of tumour antigens and low efficiency of 
antigen presentation. To overcome these problems, we 
utilized nsPEF technology to improve tumour immu-
notherapy. The results confirmed that the application of 
nsPEF can promote the phagocytosis of tumour proteins 
and improve the immunogenicity of tumour antigens, 
thereby enhancing the antitumour effect of lympho-
cytes. In addition, the nsPEF technique has good bio-
safety and is noninvasive. In summary, this modality 
and the related mechanisms may be valuable for the fu-
ture development of immunotherapies and can provide 
insights for tumour treatment.
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